**Abstract**

**Objective**: Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant schizophrenia. Clozapine is underutilized in the management of treatment-resistant schizophrenia. To understand contributing factors, we analyzed the time course and causes of clozapine discontinuations that occurred over a 20-year period in a clinical setting.

**Method**: The reasons for discontinuation and duration of clozapine treatment from a retrospective database of 138 patients with schizophrenia who had prescribed clozapine at least a month were reviewed, with the motives for discontinuation coded. The causes for termination were analyzed.

**Results**: Over two-thirds of the patient had ceased clozapine. The two most common causes for discontinuation were side-effects (51%), and own decision (29%). Somnolence accounted for 31% of all side-effects induced discontinuations. Hematological problems accounted for 21% of side-effect. The Maximal treatment dose of clozapine was higher in continuation group (411.31mg) than in discontinuation group (340.89mg). The CGI-S score when prescribing clozapine last was higher in discontinuation group than in continuous group. The patients who took atypical antipsychotics before clozapine tended to cease clozapine because of side-effects than who took typical agent.

**Conclusions**: Future studies should seek various methods to relieve side-effects of clozapine. Prospective researches using more objective tools are needed to clarify the reason for clozapine discontinuation.

**Key words**: schizophrenia, clozapine, antipsychotics, treatment discontinuation, side-effect
